Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers

E. Conde, B. Angulo, E. Izquierdo, L. Paz-Ares, C. Belda-Iniesta, M. Hidalgo, F. López-Ríos

Research output: Contribution to journalArticlepeer-review

Abstract

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.

Original languageEnglish (US)
Pages (from-to)503-508
Number of pages6
JournalClinical and Translational Oncology
Volume15
Issue number7
DOIs
StatePublished - Jul 2013

Keywords

  • ALK
  • Biomarkers
  • EGFR
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers'. Together they form a unique fingerprint.

Cite this